LONDON--(BUSINESS WIRE)--Sept. 6, 2006--A combination treatment regimen of CRESTOR(TM) (rosuvastatin) 40 mg and ezetimibe 10 mg demonstrated a 46% reduction in levels of C-reactive protein (CRP), a marker of inflammation and risk factor for cardiovascular disease, in high-risk patients. In just six weeks, the combination regimen also helped more than half (58%) of patients achieve dual CRP/LDL-C goals.(1) These post-hoc analysis findings from the EXPLORER(a) study will be presented for the first time this week at the World Congress of Cardiology in Barcelona. Previous EXPLORER results released at ISA in June showed high-risk patients achieved an unprecedented 70% reduction in LDL-C using CRESTOR combination therapy.(2)
